نتایج جستجو برای: alk kinase

تعداد نتایج: 231548  

Journal: :Frontiers in Pharmacology 2023

ALK gene missense mutations are conventionally considered non-driver without pathological significance, and therefore, there is a lack of effective target drugs against them. The standard treatment option for patients with chemotherapy or antiangiogenic agents, which usually results in unsatisfactory outcomes. Herein, we present the case patient metastatic lung adenocarcinoma harboring only mut...

2013
Damini Chand Yasuo Yamazaki Kristina Ruuth Christina Schönherr Tommy Martinsson Per Kogner Edward F. Attiyeh John Maris Olena Morozova Marco A. Marra Miki Ohira Akira Nakagawara Per-Erik Sandström Ruth H. Palmer Bengt Hallberg

Neuroblastoma is a childhood extracranial solid tumour that is associated with a number of genetic changes. Included in these genetic alterations are mutations in the kinase domain of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase (RTK), which have been found in both somatic and familial neuroblastoma. In order to treat patients accordingly requires characterisation of these muta...

Journal: :Blood 2007
Annamaria Galietta Rosalind H Gunby Sara Redaelli Paola Stano Cristiana Carniti Angela Bachi Philip W Tucker Carmen J Tartari Ching-Jung Huang Emanuela Colombo Karen Pulford Miriam Puttini Rocco G Piazza Holger Ruchatz Antonello Villa Arianna Donella-Deana Oriano Marin Danilo Perrotti Carlo Gambacorti-Passerini

The oncogenic fusion tyrosine kinase nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) induces cellular transformation in anaplastic large-cell lymphomas (ALCLs) carrying the t(2;5) chromosomal translocation. Protein-protein interactions involving NPM/ALK are important for the activation of downstream signaling pathways. This study was aimed at identifying novel NPM/ALK-binding proteins that m...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Johannes M Heuckmann Hyatt Balke-Want Florian Malchers Martin Peifer Martin L Sos Mirjam Koker Lydia Meder Christine M Lovly Lukas C Heukamp William Pao Ralf Küppers Roman K Thomas

PURPOSE ALK rearrangement-positive lung cancers can be effectively treated with ALK inhibitors. However, the magnitude and duration of response is heterogeneous. In addition, acquired resistance limits the efficacy of ALK inhibitors, with most upfront resistance mechanisms being unknown. EXPERIMENTAL DESIGN By making use of the Ba/F3 cell line model, we analyzed the cytotoxic efficacy of ALK ...

2015
Federica Lovisa Giorgio Cozza Andrea Cristiani Alberto Cuzzolin Alessandro Albiero Lara Mussolin Marta Pillon Stefano Moro Giuseppe Basso Angelo Rosolen Paolo Bonvini

ALK inhibitor crizotinib has shown potent antitumor activity in children with refractory Anaplastic Large Cell Lymphoma (ALCL) and the opportunity to include ALK inhibitors in first-line therapies is oncoming. However, recent studies suggest that crizotinib-resistance mutations may emerge in ALCL patients. In the present study, we analyzed ALK kinase domain mutational status of 36 paediatric AL...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2011
Alice T Shaw Benjamin Solomon

Several decades of cancer research have revealed a pivotal role for tyrosine kinases as key regulators of signaling pathways, controlling cell growth and differentiation. Deregulation of tyrosine kinase-mediated signaling occurs frequently in cancer and is believed to drive the initiation and progression of disease. Chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma ki...

Journal: :Cancer research 2001
A Slupianek M Nieborowska-Skorska G Hoser A Morrione M Majewski L Xue S W Morris M A Wasik T Skorski

The NPM/ALK fusion gene, formed by the t(2;5) translocation in a subset of anaplastic large cell lymphomas, encodes a Mr 75,000 hybrid protein that contains the NH2-terminal portion of the nucleolar phosphoprotein nucleophosmin (NPM) joined to the entire cytoplasmic portion of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK). NPM/ALK encodes a constitutively activated tyrosine kina...

Journal: :Cancer research 2011
Avaniyapuram Kannan Murugan Mingzhao Xing

Thyroid cancer is the most common endocrine cancer, and targeted approaches to treat it pose considerable interest. In this study, we report the discovery of ALK gene mutations in thyroid cancer that may rationalize clinical evaluation of anaplastic lymphoma kinase (ALK) inhibitors in this setting. In undifferentiated anaplastic thyroid cancer (ATC), we identified two novel point mutations, C35...

2011
Avaniyapuram Kannan Murugan Mingzhao Xing

Thyroid cancer is the most common endocrine cancer, and targeted approaches to treat it pose considerable interest. In this study, we report the discovery of ALK gene mutations in thyroid cancer that may rationalize clinical evaluation of anaplastic lymphoma kinase (ALK) inhibitors in this setting. In undifferentiated anaplastic thyroid cancer (ATC), we identified two novel point mutations, C35...

2018
Ryohei Katayama

The anaplastic lymphoma kinase (ALK) gene encodes a receptor tyrosine kinase, and many kinds of ALK fusion genes have been found in a variety of carcinomas. There is almost no detectable expression of ALK in adults. However, through ALK gene rearrangement, the resultant ALK fusion protein is aberrantly overexpressed and dimerized through the oligomerization domains, such as the coiled-coil doma...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید